Contents
Drug competition: The Waxman-Hatch Act revisited
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Virabhak, Suchin | - |
| dc.contributor.author | Sohn, Wook | - |
| dc.date.available | 2018-12-06T04:46:37Z | - |
| dc.date.created | 2018-01-02 | - |
| dc.date.issued | 2007 | - |
| dc.identifier.issn | 1538-5698 | - |
| dc.identifier.uri | http://archives.kdischool.ac.kr/kdi_dev/handle/11125/28824 | - |
| dc.identifier.uri | 10.1300/J371v15n02_02 | - |
| dc.description.abstract | This paper examines generic competition following the enactment of the 1984Waxman-Hatch Act. Unlike the existing literature, we employ antibiotics as a control group to infer legislation-induced increases in generic competition. Using FDA drug approval data, we find evidence that the Act enhanced generic competition, resulting in 1.5 times more competition between nonantibiotic drugs than between antibiotics. Moreover, the Act's overall impact is greater for newer drugs than older drugs. Copyright © by The Haworth Press, Inc. All rights reserved. | - |
| dc.language | English | - |
| dc.publisher | Haworth Press Inc. | - |
| dc.subject | antibiotic agent | - |
| dc.subject | generic drug | - |
| dc.subject | non prescription drug | - |
| dc.subject | trichlormethiazide | - |
| dc.subject | drug approval | - |
| dc.subject | drug competition | - |
| dc.subject | drug cost | - |
| dc.subject | drug efficacy | - |
| dc.subject | drug industry | - |
| dc.subject | drug manufacture | - |
| dc.subject | drug marketing | - |
| dc.subject | drug safety | - |
| dc.subject | expiration date | - |
| dc.subject | food and drug administration | - |
| dc.subject | law | - |
| dc.subject | policy | - |
| dc.subject | priority journal | - |
| dc.subject | review | - |
| dc.title | Drug competition: The Waxman-Hatch Act revisited | - |
| dc.type | Article | - |
| dc.identifier.bibliographicCitation | JOURNAL OF PHARMACEUTICAL FINANCE, ECONOMICS AND POLICY, v.15, no.2, pp.3 - 20 | - |
| dc.description.journalClass | 1 | - |
| dc.description.isOpenAccess | N | - |
| dc.citation.endPage | 20 | - |
| dc.citation.number | 2 | - |
| dc.citation.startPage | 3 | - |
| dc.citation.title | JOURNAL OF PHARMACEUTICAL FINANCE, ECONOMICS AND POLICY | - |
| dc.citation.volume | 15 | - |
| dc.contributor.affiliatedAuthor | Sohn, Wook | - |
| dc.identifier.doi | 10.1300/J371v15n02_02 | - |
| dc.identifier.scopusid | 2-s2.0-34248996517 | - |
| dc.type.docType | Review | - |
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Click the button and follow the links to connect to the full text. (KDI CL members only)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.